* 中国生物制药公司--三生制药1530.HK周二早盘一度狂飙51.7%，和辉瑞PFE.N签署总价值约60亿美元的抗癌药物许可协议。
* 三生制药公告称，公司与辉瑞就PD-1/VEGF双特异性抗体SSGJ-707订立许可协议，辉瑞将获得该产品在全球（不包括中国内地）的独家开发及商业化权利。公司将获得12.5亿美元的首付款，及最高可达48亿美元的开发、监管批准和销售里程碑付款。公司还将获得许可地区产品净销售额的两位数百分比梯度特许权使用费。
SSGJ-707获国家药品监督管理局药品审评中心（CDE）突破性治疗药物认定，适应症为一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌（NSCLC）。
* 年初迄今，三生制药累计大涨逾2.3倍。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 崔珠珠；审校 田镧沁)
((zhuzhu.cui@thomsonreuters.com; +86-21-20830048;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.